Evaluation of the Effectiveness of Dry Needling Versus Foam Roller
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04600830 |
|
Recruitment Status :
Completed
First Posted : October 23, 2020
Last Update Posted : May 11, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Myofascial Pain Syndromes Dry Needling | Procedure: Dry needling | Not Applicable |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 45 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Double (Participant, Investigator) |
| Masking Description: | A simple blind masking will be carried out to reduce biases in the interpretation of the results. The researchers responsible for the observation, measurement of the ankle ROM and Counter Movement Jump, will not be informed of the treatment performed at the time of immediate post-treatment and post-treatment at 24 hours. |
| Primary Purpose: | Treatment |
| Official Title: | Evaluation of the Effectiveness of Dry Needling Against Foam Roller in the Short Term, Healthy Athletes With Reduced Mobility of the Ankle Joint |
| Actual Study Start Date : | May 1, 2020 |
| Actual Primary Completion Date : | May 15, 2020 |
| Actual Study Completion Date : | May 10, 2021 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Dry Needling Group
Dry needling will be applied to the myofascial trigger points of the gastrocnemius muscle. With the dry needle (0.3 x 40 mm. Myofib, Toledo, Spain). Thus, insert the needle until you get the first twitch response. Once the first twitch response is obtained, the needle will move about 2-3 mm vertically quickly. Twenty-five insertions without leaving the skin. The approximate frequency of 1 Hz for 25 to 30 seconds.
|
Procedure: Dry needling
Intervention with deep dry needling on latent myofascial trigger points (MTrPs) in gastrocnemius muscle. |
|
Active Comparator: Foam Roller Group
The myofascial self-release technique with the FR Black Roll PRO (Bottighogen, Switzerland). The subject will move his body in the same direction as the muscle fibers, using his hands to propel and get the roller to slide back and forth. The device will only be applied at the muscular level, avoid the area of the Achilles tendon. It will be repeated on the contralateral leg. A total of three 60-second steps is executed on each leg and a 30-second break between both.
|
Procedure: Dry needling
Intervention with deep dry needling on latent myofascial trigger points (MTrPs) in gastrocnemius muscle. |
- Range of motion (ROM) [ Time Frame: 48 hours ]Range of motion (ROM) is a key measurement to help in detecting and diagnosing musculoskeletal deficits, monitoring treatment progression, and guiding the treatment plan. Measurement of ROM is a relevant point and an important item of the joint evaluation process when using any ankle scoring system as part of the ankle and ankle joint evaluation. ROM of ankle joint in load PRE, POST treatment and POST 24 hours after of intervention.
- Lunge / Ankle Test Test [ Time Frame: 48 hours ]he Weight-bearing lunge test (WBLT) or Dorsiflexion Lunge Test (DFT) is used to assess the dorsiflexion range of movement (DROM) at the ankle joint. Participants are instructed to lunge forward until their knee touches the wall (vertical line). The heel is required to remain in contact with the floor at all times. The foot is moved away from the wall to the point where the knee can only make slight contact with the Wall.
- Counter Movement Jump (CMJ) [ Time Frame: 48 hours ]The countermovement jump (CMJ) is a simple, practical, valid, and very reliable measure of lower-body power. This suggests that performances in the CMJ are linked with maximal speed, maximal strength, and explosive-strength. When the CMJ is performed using the arm-swing, performances can be ≥10% higher than when they include no arm-swing. Contact mats, force platforms, accelerometers, high-speed cameras, and infrared platforms have all been shown to provide a valid and reliable measure of CMJ performance - though force platforms are considered as the 'gold-standard'.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 35 Years (Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Students of physiotherapy degree of the university
- All participants who present restriction on active ankle dorsiflexion (<35º).
- They must be diagnosed through manual therapy of latent PG in the gastro-soleus complex.
Exclusion Criteria:
- Subjects suffering from belonephobia
- Pathology of connective tissue
- Coagulation problems
- Lymphatic disorders
- Diabetes
- Surgical history in the lower limb (last 12 months)
- Prior treatment with dry needling (last 6 months)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04600830
| Spain | |
| Juan Vicente Mampel | |
| Valencia, Spain, 46021 | |
| Principal Investigator: | Juan Vicente | Fundacion UCV |
| Responsible Party: | Fundación Universidad Católica de Valencia San Vicente Mártir |
| ClinicalTrials.gov Identifier: | NCT04600830 |
| Other Study ID Numbers: |
UCV/2019 - 2020/062 |
| First Posted: | October 23, 2020 Key Record Dates |
| Last Update Posted: | May 11, 2021 |
| Last Verified: | May 2021 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Dry needling Myofascial pain syndromes Ankle joint |
|
Myofascial Pain Syndromes Fibromyalgia Muscular Diseases Musculoskeletal Diseases |
Rheumatic Diseases Neuromuscular Diseases Nervous System Diseases |

